Trial reportClinical journal of the American Society of Nephrology : CJASN2015
Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis.
Trial report in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Beta-blocker efficacy for intra- and interdialytic hypertension patients: a systematic review and meta-analysis.International urology and nephrology · 2024Pooled it
- The effect of exercise on vascular health in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.American journal of physiology. Renal physiology · 2023Pooled it
- Interventions for fatigue in people with kidney failure requiring dialysis.The Cochrane database of systematic reviews · 2023Pooled it
- Should We Use Renin-Angiotensin-System Inhibitors As a First-Line Therapy for the Management of Hypertension in Patients Receiving Hemodialysis?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Article
- Beta-blockers in patients with intradialytic hypertension: are they potent anti-hypertensives?International urology and nephrology · 2024Article
- Pharmacologic Therapies for Aortic Stiffness in End-Stage Renal Disease: A Systematic Review and Meta-Analysis.Canadian journal of kidney health and disease · 2020Article
- Effects of renal denervation on blood pressure in hypertensive patients with end-stage renal disease: a single centre experience.Clinical and experimental nephrology · 2019Article
- Blood pressure control in conventional hemodialysis.Seminars in dialysis · 2018Review
- Arterial stiffness in end-stage renal disease-pathogenesis, clinical epidemiology, and therapeutic potentials.Hypertension research : official journal of the Japanese Society of Hypertension · 2018Review
- Blood Pressure and Risk of Cardiovascular Events in Patients on Chronic Hemodialysis: The CRIC Study (Chronic Renal Insufficiency Cohort).Hypertension (Dallas, Tex. : 1979) · 2017Article
- Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis.Nature reviews. Nephrology · 2016Review
- Cardiovascular disease: Questioning the effect of β-blockers on vascular stiffness.Nature reviews. Nephrology · 2015Article
- Reducing arterial stiffness in CKD: revising the paradigms.Clinical journal of the American Society of Nephrology : CJASN · 2015Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesWhether improvements in arterial compliance with BP lowering are because of BP reduction alone or if pleiotropic effects of antihypertensive agents contribute remains unclear. It was hypothesized that, among patients on hemodialysis, compared with a β-blocker (atenolol), a lisinopril-based therapy will better reduce arterial stiffness. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 200 participants of the Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril Trial, 179 patients with valid assessment of aortic pulse wave velocity at baseline (89 patients randomly assigned to open-label lisinopril and 90 patients randomly assigned to atenolol three times a week after dialysis) were included in the secondary analysis. Among them, 109 patients had a valid pulse wave velocity measurement at 6 months. Monthly measured home BP was targeted to <140/90 mmHg by addition of antihypertensive drugs and dry weight adjustment. The difference between drugs in percentage change of aortic pulse wave velocity from baseline to 6 months was analyzed.
resultsContrary to the hypothesis, atenolol-based treatment induced greater reduction in aortic pulse wave velocity relative to lisinopril (between drug difference, 14.8%; 95% confidence interval, 1.5% to 28.5%; P=0.03). Reduction in 44-hour ambulatory systolic and diastolic BP was no different between groups (median [25th, 75th percentile]; atenolol: -21.5 [-37.7, -7.6] versus lisinopril: -15.8 [-28.8, -1.5] mmHg; P=0.27 for systolic BP; -14.1 [-22.6, -5.3] versus -10.9 [-18.4, -0.9] mmHg, respectively; P=0.30 for diastolic BP). Between-drug difference in change of aortic pulse wave velocity persisted after adjustments for age, sex, race, other cardiovascular risk factors, and baseline ambulatory systolic BP but disappeared after adjustment for change in ambulatory systolic BP (11.8%; 95% confidence interval, -2.3% to 25.9%; P=0.10).
conclusionsAmong patients on dialysis, atenolol was superior in improving arterial stiffness. However, differences between atenolol and lisinopril in improving aortic stiffness among patients on hemodialysis may be explained by BP-lowering effects of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.